Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event
March 16, 2017 15:52 ET
|
Gemphire Therapeutics
LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update
March 15, 2017 16:01 ET
|
Gemphire Therapeutics
Announces Date for 2017 Annual Meeting of Stockholders Conference Call and Live Webcast, Today at 4:30 Eastern Time LIVONIA, Mich., March 15, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc....
Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15
March 13, 2017 06:30 ET
|
Gemphire Therapeutics
LIVONIA, Mich., March 13, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Announces $12.5 Million Financing
March 10, 2017 09:33 ET
|
Gemphire Therapeutics
LIVONIA, Mich., March 10, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference
February 02, 2017 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial
January 30, 2017 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced interim data on the LDL-C primary endpoint from the ongoing open label COBALT-1...
Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 18, 2017 17:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on January 16, 2017, the Compensation Committee of its Board of Directors, which is...
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
January 09, 2017 08:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof...
Gemphire Therapeutics Provides Clinical Update
January 05, 2017 08:39 ET
|
Gemphire Therapeutics
Enrollment in the ROYAL-1 Clinical Trial Investigating Gemcabene in Hypercholesterolemia Is Ahead of Plan and Expected to be Completed This Month – Data Expected in the Third Quarter of 2017 Interim...
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 29, 2016 16:15 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on November 25, 2016, the Compensation Committee of its Board of Directors, which...